Blue Jet Healthcare Ltd Q1 FY27 Earnings Analysis

- **Pharmaceutical Intermediates (PI) Vertical**: Expected to be resilient with the ability to pass on pricing, ensuring top-line and margin sustainability. - **Contrast Media Business**: Anticipated double-digit growth in FY27 driven by volume growth and new product launches, including iodinated and gadolinium contrast media. Trial orders from new customers (e.g., in Japan) encourage optimism. - **New Product Launches**: Several product validations and commercial launches expected in FY27 across contrast media and PI segments. - **Product Pipeline**: Strengthened pipeline with ~20 active RFPs, including GLP-1 related intermediates and peptides; two lateral stage opportunities may commercialize, with dedicated capacity expected at Vizag. - **Volume Growth**: FY27 growth driven partly by volume increase and new launches, aiming to exceed previous peak sales levels, especially in PI. - **Peptides and Strategic Positioning**: Ongoing capability building and initial lab supplies to innovators indicate future growth avenues.

- FY26 was foundational with investments in manufacturing, R&D, and customer engagement, aimed at next-phase growth. - Improved visibility in FY27 driven by healthy customer engagement and confirmed order visibility, particularly in contrast media and select pharma intermediates (PI) programs. - Expectation of double-digit growth in contrast media, partly due to new product launches. - PI/API segment to recover and grow beyond FY25 peak after inventory normalization, supported by new product launches and lateral entry opportunities at Vizag (24-30 months timeline). - Investments in Vizag greenfield expansion to bolster long-term growth capacity. - Margins expected to stabilize with pass-through pricing mechanisms; cost structures to be clearer post Q1 FY27. - EBITDA margin in FY26 was muted (31%) due to volume dips but structural growth investments should support future margin expansion. - Operating efficiencies balanced with strategic positioning for sustained growth. - Earnings expected to grow as capacity ramps up and new commercial opportunities commercialize, with careful management of raw material and logistic costs.

- Total capex planned for Vizag greenfield project: ~INR 1,000 crores over ~3 years. - Vizag Phase 1 to develop dedicated manufacturing blocks for contrast media intermediates, high-intensity sweeteners, and pharma intermediates. - Additional capex of ~INR 400 crores planned for FY27 towards Vizag completion, Mahad facility completion, and Ambernath additions. - Mahad Unit 3 backward integration project (final stages) to commence production in H2 FY27, enhancing supply chain resilience. - New R&D center planned in Hyderabad with ~INR 40 crores investment focusing on peptides, GLP-1 linked opportunities, biocatalysts, and faster CDMO development. - Accelerating capex plans supported by strong liquidity; company remains debt-free. - Investments are aligned with customer engagements and long-term business visibility, targeting medium to long-term growth.

- The company is currently well-positioned as a debt-free entity with healthy liquidity. - Management describes the fundraising situation as dynamic and will provide updates in coming quarters. - There are no immediate plans for fundraising at this stage. - Capital expenditure plans are being accelerated using existing liquidity without the need for external debt or equity. - No specific fundraising is being planned for the Vizag greenfield investment at this moment. - Management intends to keep investors informed about any changes related to capital raising in future disclosures.

- Inventory destocking in the pharma intermediates (PI) segment has completed, and shipments have resumed to optimum capacity (Page 16). - Additional new orders have been received on the PI side after supply chain realignment, boosting confidence in good upcoming numbers (Page 9). - Contrast media segment shows increasing offtake requirements due to deeper partnerships and new product launches (Page 9). - The entire INR190 crore Q4 revenue in contrast media relates to actual shipments, with no significant goods in transit variance (Page 10). - Approximately 20 active RFPs are being tracked in PI and CDMO segments, mainly in chronic therapeutic areas including GLP-1 and peptides (Page 5). - Two of these RFP opportunities are expected to move into commercialization in the current year (Page 5). - Two high conviction commercial stage lateral entry opportunities are being evaluated with dedicated capacity planned at Vizag (Page 5). - Overall, order visibility is improving with new product launches expected in both PI and contrast media segments (Pages 5, 9, 16).